Drug Trial Radar · NCT01794793
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
Last checked: Nov 20, 2026Latest source record: Oct 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
337
Actual
Start
Jun 10, 2013
Primary completion
Jul 25, 2023
Study completion Jul 25, 2023
Sponsor
- Lead sponsor
- RECORDATI GROUPIndustry
- Sponsor type
- Industry
- First posted
- Feb 20, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
Conditions
- Cushing's Disease
- Acromegaly
- Neuroendocrine Tumors
- Pituitary Tumors
- Ectopic ACTH Secreting (EAS) Tumors
- Dumping Syndrome
- Prostate Cancer
- Melanoma Negative for bRAF
- Melanoma Negative for nRAS
Interventions
PasireotideDrug
Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.
CabergolineDrug
Cabergoline tablet 0.5mg or 1.0mg taken by mouth once daily may be combined with subcutaneous formulation of pasireotide for Cushing's Disease or Acromegaly. Dose is dependent on parent study guidelines.
Pasireotide LARDrug
Long Acting Release is administered by a single intramuscular (i.m.) monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events to Evaluate Long Term Safety DataTime frame: Baseline up to approximately 10 years
Locations
94 sites in 28 countries. Site status is shown where the registry gives one.
Ximed Research SC - SOM230B2412
La Jolla, California
Cedars Sinai Medical Center Cedars Sinai 4
Los Angeles, California
Stanford Universtiy Medical Center Stanford Hospital & Clinics
Stanford, California
University of Michigan Comprehensive Cancer Center SC-2
Ann Arbor, Michigan
Memorial Sloan-Kettering Cancer Center SC
New York, New York
Virginia Endocrinology Research SC
Chesapeake, Virginia
Swedish Cancer Institute Swedish Cancer Institute (SC)
Seattle, Washington
Recordati Investigative Site
CABA, Buenos Aires, Argentina
Recordati Investigative Site
Mar del Plata, Buenos Aires, Argentina
Recordati Investigative Site
Bruges, Belgium
Recordati Investigative Site
Brussels, Belgium
Recordati Investigative Site
Brussels, Belgium
Recordati Investigative Site
Ghent, Belgium
Recordati Investigative Site
Leuven, Belgium
Recordati Investigative Site
Liège, Belgium
Recordati Investigative Site
Wilrijk, Belgium
Recordati Investigative Site
Edegem, Antwerpen, Belgium
Recordati Investigative Site
Fortaleza, Ceará, Brazil
Recordati Investigative Site
Curitiba, Paraná, Brazil
Recordati Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Recordati Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Recordati Investigative Site
Joinville, Santa Catarina, Brazil
Recordati Investigative Site
Botucatu, São Paulo, Brazil
Recordati Investigative Site
São Paulo, São Paulo, Brazil
Recordati Investigative Site
Sofia, Bulgaria
Recordati Investigative Site
Halifax, Nova Scotia, Canada
Recordati Investigative Site
London, Ontario, Canada
Recordati Investigative Site
Montreal, Quebec, Canada
Recordati Investigative Site
Montreal, Quebec, Canada
Recordati Investigative Site
Angers, France
Recordati Investigative Site
Bron, France
Recordati Investigative Site
Le Kremlin-Bicêtre, France
Recordati Investigative Site
Lille, France
Recordati Investigative Site
Marseille, France
Recordati Investigative Site
Pessac, France
Recordati Investigative Site
Pierre-Bénite, France
Recordati Investigative Site
Toulouse, Cedex 9, France
Recordati Investigative Site
Berlin, Germany
Recordati Investigative Site
Hamburg, Germany
Recordati Investigative Site
München, Germany
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.